Long-term follow-up data of 4512 patients with complete information between 2000 and 2016 with a median follow-up of 9.1 years, confirmed no significant difference between low-risk, margin-negative TZ or CZ/PZ tumours with regards PSA failure or early treatment rates (p = 0.652). The gene discussed is KLK3; the disease is neoplasm.